LON:SNG Synairgen (SNG) Share Forecast, Price & News GBX 8.20 -0.30 (-3.53%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range 7.60▼ 8.5850-Day Range 7.43▼ 16.5052-Week Range 7.01▼ 36.48Volume539,441 shsAverage Volume508,413 shsMarket Capitalization£16.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About Synairgen (LON:SNG) StockSynairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.Read More Receive SNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synairgen and its competitors with MarketBeat's FREE daily newsletter. Email Address SNG Stock News HeadlinesApril 30, 2023 | americanbankingnews.comSynairgen (LON:SNG) Stock Price Passes Below 200-Day Moving Average of $14.31April 7, 2023 | americanbankingnews.comSynairgen (LON:SNG) Reaches New 52-Week Low at $7.01June 8, 2023 | UNKNOWN (Ad)The Stock That's Brining Lithium Back To America!The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S SoilApril 7, 2023 | americanbankingnews.comSynairgen (LON:SNG) Sets New 12-Month Low at $7.01January 4, 2023 | finance.yahoo.comCompanies Like Synairgen (LON:SNG) Could Be Quite RiskyOctober 4, 2022 | proactiveinvestors.comFTSE 100 jumps 140 points as L&G statement reassures - Proactive Investors USAOctober 4, 2022 | finance.yahoo.comSynairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19October 4, 2022 | businesswire.comSynairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 - Business WireJune 8, 2023 | UNKNOWN (Ad)The Stock That's Brining Lithium Back To America!The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S SoilSeptember 30, 2022 | marketwatch.comSynairgen Shares Drop Amid Phase 3 Study Issues; Pretax Loss Narrows - MarketWatchSeptember 29, 2022 | lse.co.ukEARNINGS SUMMARY: Angle revenue up; Synairgen, Bango loss widens | Financial News - London South EastSeptember 29, 2022 | proactiveinvestors.comTesla appoints Airbnb co-founder Joe Gebbia to board - Proactive Investors USASeptember 20, 2022 | finance.yahoo.comSynairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022September 20, 2022 | marketscreener.comSynairgen's SNG001 Reduces Long COVID-19 Symptoms In Follow-up Visits After Late-stage Trial - Marketscreener.comSeptember 20, 2022 | proactiveinvestors.comSynairgen to present data showing drug lowers risk of long Covid symptoms - Proactive Investors USASeptember 7, 2022 | lse.co.ukIN BRIEF: Synairgen shares rise as positive data found for COPD | Financial News - London South EastSeptember 7, 2022 | finance.yahoo.comSynairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patientsSeptember 7, 2022 | lse.co.ukSynairgen unveils positive clinical trial data | Financial News - London South EastSeptember 7, 2022 | marketwatch.comSynairgen Gets Positive Data From Trial of Respiratory Drug Treatment - MarketWatchSeptember 7, 2022 | proactiveinvestors.comSynairgen reports positive data from respiratory viral infection drug - Proactive Investors USASeptember 5, 2022 | proactiveinvestors.comFTSE 100 opens lower as oil giants push ahead - Proactive Investors USASeptember 5, 2022 | morningstar.co.ukTRADING UPDATES: Bradda wins drilling approval; Oakley invests in vLex - MorningstarSeptember 5, 2022 | proactiveinvestors.comSynairgen to play key role in respiratory viral infection study - Proactive Investors USAAugust 5, 2022 | fool.co.ukThe Synairgen share price crashes again as US study is haltedJune 29, 2022 | globenewswire.comChronic Obstructive Pulmonary Disease Clinical Trial Pipeline Insights | DelveInsight - GlobeNewswireMay 31, 2022 | finance.yahoo.comCan Synairgen (LON:SNG) Afford To Invest In Growth?May 27, 2022 | morningstar.co.ukIN BRIEF: Synairgen shares fall as loss widens on higher costs - MorningstarSee More Headlines SNG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNG Company Calendar Last Earnings9/29/2020Today6/08/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SNG CUSIPN/A CIKN/A Webwww.synairgen.com Phone+44-23-80512800FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-17,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.62% Return on Assets-37.22% Debt Debt-to-Equity Ratio0.09 Current Ratio7.19 Quick Ratio6.35 Sales & Book Value Annual Sales£79,000.00 Price / Sales201.38 Cash FlowGBX 4.16 per share Price / Cash Flow1.90 Book ValueGBX 10 per share Price / Book0.79Miscellaneous Outstanding Shares201,380,000Free FloatN/AMarket Cap£15.91 million OptionableNot Optionable Beta-2.27 Key ExecutivesMr. Richard Marsden (Age 55)CEO, MD & Exec. Director Comp: $328kProf. Stephen T. Holgate CBE (Age 75)M.D., Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board Comp: $44kMr. John Ward (Age 61)CFO & Exec. Director Comp: $240kDr. Phillip David Monk (Age 54)Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director Comp: $240kProf. Donna DaviesCo-Founder & Member of Scientific Advisory BoardProf. Ratko DjukanovicCo-Founder & Member of Scientific Advisory BoardMs. Brooke S ClarkeSr. VP & Head of CommunicationsDr. Gareth E. Walters Ph.D. (Age 64)Chief Regulatory Officer Ms. Jody BrookesSr. VP & Head of Clinical OperationsMr. Richard Hennings (Age 53)Chief Commercial Officer More ExecutivesKey CompetitorsHemogenyx PharmaceuticalsLON:HEMONetScientificLON:NSCIAorTech InternationalLON:AOROxford BioDynamicsLON:OBDRealm TherapeuticsLON:RLMView All Competitors SNG Stock - Frequently Asked Questions How have SNG shares performed in 2023? Synairgen's stock was trading at GBX 13.50 at the start of the year. Since then, SNG stock has decreased by 41.5% and is now trading at GBX 7.90. View the best growth stocks for 2023 here. How were Synairgen's earnings last quarter? Synairgen plc (LON:SNG) announced its earnings results on Tuesday, September, 29th. The company reported ($3.11) earnings per share for the quarter. What other stocks do shareholders of Synairgen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synairgen investors own include Alibaba Group (BABA), Yamana Gold (YRI), Eldorado Gold (ELD), Ocado Group (OCDO), Polo Resources (POL), Silvercorp Metals (SVM), W Resources (WRES), Associated British Foods (ABF), Ariana Resources (AAU) and First Majestic Silver (AG). What is Synairgen's stock symbol? Synairgen trades on the London Stock Exchange (LON) under the ticker symbol "SNG." How do I buy shares of Synairgen? Shares of SNG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Synairgen's stock price today? One share of SNG stock can currently be purchased for approximately GBX 7.90. How much money does Synairgen make? Synairgen (LON:SNG) has a market capitalization of £15.91 million and generates £79,000.00 in revenue each year. The company earns £-17,640,000.00 in net income (profit) each year or GBX (0.08) on an earnings per share basis. How can I contact Synairgen? Synairgen's mailing address is Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom. The official website for the company is www.synairgen.com. The company can be reached via phone at +44-23-80512800. This page (LON:SNG) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synairgen plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.